Scandion Oncology develops targeted therapies that inhibit chemotherapy resistance mechanisms in cancer cells, specifically through its lead compound SCO-101. This approach aims to enhance the efficacy of existing chemotherapy treatments, improving outcomes for patients with resistant tumors.
Funding
$902.2K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to chemotherapy, limiting the effectiveness of treatment and leading to poorer outcomes for patients. This resistance often arises from mechanisms within the cancer cells that actively pump out the drugs or alter their metabolism, reducing their ability to kill the tumor. Overcoming these resistance mechanisms is a significant challenge in oncology.
Solution
Scandion Oncology is developing targeted therapies to address chemotherapy resistance in cancer cells. Their lead compound, SCO-101, inhibits drug efflux pumps, specifically ABCG2 and UGT1A1, which are key drivers of resistance. By blocking these pumps, SCO-101 aims to increase the intracellular concentration of chemotherapeutic agents in resistant tumor cells, thereby restoring their sensitivity to treatment. This approach has the potential to enhance the efficacy of existing chemotherapy regimens and improve outcomes for patients with drug-resistant cancers. The company is currently studying SCO-101 in metastatic colorectal cancer (mCRC) and developing it for pancreatic cancer.
Target Audience
The primary target audience includes patients with cancers that have developed resistance to chemotherapy, as well as oncologists and researchers seeking new strategies to overcome drug resistance.
Features
- SCO-101: A small molecule inhibitor targeting ABCG2 and UGT1A1 drug efflux pumps.
- Biomodulation capabilities to revert drug resistance in cancer cells.
- Phase 2 clinical trial (CORIST) ongoing in metastatic colorectal cancer (mCRC).
- Phase 1 program (PANTAX) developing SCO-101 for pancreatic cancer.
- Aims to increase the efficacy of existing chemotherapy treatments.